Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Common Equity (2016 - 2025)

Historic Common Equity for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $1.3 million.

  • Lifecore Biomedical, Inc. \De\'s Common Equity fell 8819.27% to $1.3 million in Q2 2025 from the same period last year, while for May 2025 it was $1.3 million, marking a year-over-year decrease of 8819.27%. This contributed to the annual value of $1.3 million for FY2025, which is 8819.27% down from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Common Equity of $1.3 million as of Q2 2025, which was down 8819.27% from $2.2 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Common Equity ranged from a high of $202.2 million in Q1 2021 and a low of -$13.6 million during Q3 2023
  • Its 5-year average for Common Equity is $66.4 million, with a median of $26.4 million in 2023.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Common Equity plummeted by 11741.25% in 2023 and then skyrocketed by 98719.21% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Common Equity stood at $155.4 million in 2021, then crashed by 54.23% to $71.1 million in 2022, then tumbled by 98.0% to $1.4 million in 2023, then soared by 987.19% to $15.4 million in 2024, then tumbled by 91.35% to $1.3 million in 2025.
  • Its Common Equity was $1.3 million in Q2 2025, compared to $2.2 million in Q1 2025 and $15.4 million in Q4 2024.